Guardant Health and Quest Diagnostics Announce Strategic Collaboration to Broaden Access to Guardant’s Shield™ Blood-based Screening Test in the United States
DGXPALO ALTO, Calif. & SECAUCUS, N.J.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced a broad strategic collaboration to make Guardant’s Shield™ blood-based screening test available to physicians and patients served by Quest in the United States. Shield is the first and only blood test to receive full FDA approval as a primary screening option for colorectal c
Quest Diagnostics Launches Advanced Pharmacogenomics (PGx) Offering
DGX(NYSE:DGX) New Service Empowers Clinicians with Personalized Insights from Coriell Life Sciences to Optimize Prescribing Across Specialties SECAUCUS, N.J., Sept. 4, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced an advanced...
Fentanyl Positivity Is More Than Seven Times Higher in Random Tests vs. Pre-Employment Drug Screening, Finds 2025 Quest Diagnostics Drug Testing Index
DGX(NYSE:DGX) Majority of fentanyl positives also contain other drugs, with co-positivity with marijuana doubling since 2020 SECAUCUS, N.J., Sept. 2, 2025 /PRNewswire/ -- The percentage of employees in the general U.S. workforce testing positive for fentanyl in random drug tests far exceeded those in...
FDA Grants Breakthrough Device Designation for Haystack MRD Circulating Tumor DNA Test from Quest Diagnostics
DGXSECAUCUS, N.J., Aug. 25, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the company's Haystack MRD® test for...
Quest Diagnostics to Speak at the Baird 2025 Global Healthcare Conference
DGXSECAUCUS, N.J., Aug. 15, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends...
Quest Diagnostics Declares Quarterly Cash Dividend
DGXSECAUCUS, N.J., Aug. 13, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.80 per share, payable on October 20, 2025 to shareholders of record of Quest...
Mass General Brigham Launches Two Clinical Trials to Study Haystack MRD ctDNA as Guide for Post-surgical Treatment for Two Cancer Types
DGXSECAUCUS, N.J. and BOSTON, Aug. 7, 2025 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, today announced a research collaboration with Mass General Brigham investigators at Massachusetts Eye and Ear and Massachusetts General Hospital, world-renowned centers for...
Quest Diagnostics Collaborates With MD Anderson To Develop Multi-Cancer Stratification Blood Test
DGXHere's How Much You Would Have Made Owning Quest Diagnostics Stock In The Last 5 Years
DGX$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
DGXJP Morgan Maintains Neutral on Quest Diagnostics, Raises Price Target to $190
DGXPiper Sandler Maintains Neutral on Quest Diagnostics, Raises Price Target to $200
DGXHere's How Much You Would Have Made Owning Quest Diagnostics Stock In The Last 5 Years
DGXThese Analysts Boost Their Forecasts On Quest Diagnostics After Better-Than-Expected Q1 Earnings
DGXTruist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $190
DGXBarclays Maintains Equal-Weight on Quest Diagnostics, Raises Price Target to $185
DGXA Glimpse Into The Expert Outlook On Quest Diagnostics Through 12 Analysts
DGXEvercore ISI Group Maintains In-Line on Quest Diagnostics, Raises Price Target to $180
DGXBaird Maintains Outperform on Quest Diagnostics, Raises Price Target to $194
DGXQuest Diagnostics Revenue Rebound, Strategic Moves Fuel Outlook Confidence
DGXQuest Diagnostics Q1 2025 revenue rose to $2.65 billion with EPS of $2.21, exceeding expectations; full-year guidance for sales and EPS reaffirmed.
Quest Diagnostics Reaffirms 2025 Guidance For Revenue Of $10.70B-$10.85B (Vs. Cons. Of $10.78B), Adjusted EPS Of $9.55-$9.80 (Vs. Cons. Of $9.68)
DGXQuest Diagnostics Q1 2025 Adj EPS $2.21 Beats $2.15 Estimate, Sales $2.65B Beat $2.63B Estimate
DGXExamining the Future: Quest Diagnostics's Earnings Outlook
DGX$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
DGXPeering Into Quest Diagnostics's Recent Short Interest
DGXPrice Over Earnings Overview: Quest Diagnostics
DGXMizuho Maintains Outperform on Quest Diagnostics, Raises Price Target to $189
DGXQuest Diagnostics Announced The Launch Of A New Laboratory Blood Test Designed To Help Physicians Confirm Amyloid Brain Pathology Due To Alzheimer's Disease In Patients With Mild Cognitive Impairment Or Dementia
DGXRedburn Atlantic Initiates Coverage On Quest Diagnostics with Buy Rating, Announces Price Target of $195
DGXQuest Diagnostics Launches New HPV Screening Solution To Enhance Cervical Cancer Risk Detection
DGXWhat 9 Analyst Ratings Have To Say About Quest Diagnostics
DGXBaird Maintains Outperform on Quest Diagnostics, Raises Price Target to $191
DGXQuest Diagnostics Now Expects Worse-than-anticipated Weather To Create A Headwind To Revenue Of Around $25M And To EPS Of About $0.10 In The First Quarter Of 2025
DGXQuest Diagnostics Reaffirmed 2025 Guidance For Revenue Of $10.70B-$10.85B (Vs. Cons. Of $10.769B), Adjusted EPS Of $9.55-$9.80 (Vs. Cons. Of $9.71)
DGXQuest Diagnostics Provides Long-term Outlook Beyond 2025: Sees Revenues Compound Annual Growth Rate (CAGR) Of 4%-5%, Adjusted EPS Growth At 7%-9%
DGXQuest Diagnostics And Google Cloud Collaborate To Streamline Data And Personalize Customer Experiences Using Generative AI
DGXThe Analyst Verdict: Quest Diagnostics In The Eyes Of 11 Experts
DGXCitigroup Downgrades Quest Diagnostics to Neutral, Maintains Price Target to $185
DGXQuest Diagnostics Acquires Select Assets Of Fresenius's Spectra Laboratories For Dialysis Testing Services In U.S., Terms Not Disclosed
DGXGrail Shares Spiked Wednesday: What's Going On?
DGXGrail shares are trading higher Wednesday after the company announced a new collaboration with Quest Diagnostics aimed at improving provider access to its Galleri multi-cancer early detection test.
GRAIL And Quest Diagnostics Provide GRAIL's Galleri Multi-Cancer Early Detection Test Through The Quest Diagnostics Test Ordering System
DGXMainz Biomed Forms Agreement With Quest Diagnostics To Support Commercialization Of Mainz Biomed's NextGen Screening Test For Colorectal Cancer
DGXQuest Becomes Exclusive Validator For Results From The Hound Cannabis Breathalyzer
DGXHound Labs, creator of the Hound Cannabis Breathalyzer, entered into an agreement with Quest Diagnostics (NYSE: DGX), a provider of diagnostic information services.
Morgan Stanley Maintains Equal-Weight on Quest Diagnostics, Lowers Price Target to $142
DGX